CHOP is a four-drug chemotherapy regimen including cyclophosphamide (Endoxana), doxorubicin, vincristine (Oncovin) and prednisolone. It is used in the treatment of several cancers including lymphoma. Side-effects include low white blood cell counts.

Following improvements in prognosis since the introduction of combination antiretroviral therapy, HIV-positive patients taking HIV treatment now have similar outcomes to HIV-negative people when treated with CHOP for non-Hodgkin’s lymphoma.1 2 3 4 This is true even for patients with the aggressive diffuse large B-cell form of the disease.5

Patients taking CHOP may experience reduced levels of the protease inhibitors indinavir (Crixivan) or nelfinavir (Viracept), which may require monitoring of drug levels in the blood.6


  1. Lim ST et al. AIDS-related Burkitts lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol 23: 4430-4438, 2005
  2. Navarro JT et al. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. Br J Haematol 112: 909-915, 2001
  3. Vaccher E et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer 91: 155-163, 2001
  4. Weis N et al. Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort survey. Clin Infect Dis 42: 1481-1487, 2006
  5. Navarro JT et al. The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy. Haematologica 90: 704-706, 2005
  6. Cruciani M et al. Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients. J Antimicrob Chemother 55: 546-549, 2005

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.